Show Notes
The Trump administration has imposed a 15% tariff on EU pharmaceuticals and threatened even steeper levies elsewhere. At the same time, however, the government has issued ultimatums to 17 companies to cut drug costs. In this podcast, ING's Diederik Stadig explains why these competing goals cannot be reconciled, and what the strategy means for the industry - and for consumers in the US and Europe.
More from ING THINK aloud
Imagine a world where money moves instantly - across borders, systems and time zones, 24 hours a day. For many, that future rests on stablecoins: digital money, backed by real assets, designed to hold its value and move at the speed of the internet. In this podcast, experts discuss why stablecoins could shape the future of money and what it will take to make them a trusted, everyday reality.
In this podcast, ING’s Jan Frederik Slijkerman discusses the key trends that are set to define the European telecoms sector in 2026
Are Trump’s pharmaceutical policies a seismic revolution, or just hot air? Will he succeed in lowering drug prices in 2026? Will manufacturing shift to the US? And how will all of this impact Europe and China? ING's Diederik Stadig and Stephen Farrelly answer these questions and more in this week's THINK aloud.
In this podcast, ING's Diederik Stadig, Gerben Hieminga and Coco Zhang discuss the role of data centres in driving global economic growth, strategies to tackle the energy challenge, and what Europe must do to raise its game
In this podcast, ING's James Knightley and Padhraic Garvey discuss President Trump's efforts to steer monetary policy - and the economic narrative - through high-profile firings at the Federal Reserve and Bureau of Labor Statistics.